Ibrutinib Targets Mutant-Egfr Kinase With a Distinct Binding Conformation

Oncotarget - United States
doi 10.18632/oncotarget.11951
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

Cancer Discovery
Oncology
2014English

Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

Biomedical Journal of Scientific & Technical Research
2019English

Dual Blockade of EGFR Tyrosine Kinase Using Osimertinib and Afatinib Eradicates EGFR‑mutant Ba/F3 Cells

Oncology Reports
MedicineCancer ResearchOncology
2018English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2019English

Volume-Based Growth Tumor Kinetics as a Prognostic Biomarker for Patients With EGFR Mutant Lung Adenocarcinoma Undergoing EGFR Tyrosine Kinase Inhibitor Therapy: A Case Control Study

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2016English

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

The Abl SH2-kinase Linker Naturally Adopts a Conformation Competent for SH3 Domain Binding

Protein Science
BiochemistryMedicineMolecular Biology
2007English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy